between small residual set-up errors following IGRT and overall survival in lung cancer patients (mostly with significant comorbidities), and explores which anatomy may be responsible for observed differences. Method: Residual setup errors of 546 NSCLC patients treated with an off-line 5mm action threshold correction protocol for bony anatomy were summarized per patient as the mean and standard deviation for each axis, as well as the vector magnitude in a direction from tumour towards the heart, and included in multivariate Cox regression. Delivered dose distributions including residual setup errors were estimated and the difference between the delivered and planned dose was compared for patients who did/did not survive longer than 1 year. Permutation testing (n¼1000) assessed significance. Result: Residual setup errors were not correlated with any pre-treatment clinical variable. Patients with a residual shift towards the heart (mean w2 mm, max 5mm) have significantly worse overall survival (hazard ratio 1.310, p ¼ 0.001). The average dose in the heart region changes linearly with the residual shift magnitude towards the heart (w0.8Gy/ mm). A higher delivered dose than planned in a region at the heart base (Figure 1, arrow) is associated with poorer survival in multivariate analysis (hazard ratio 1.214/Gy, p<0.001). Conclusion: Small residual shifts after IGRT are strongly associated with overall survival in NSCLC patients, with shifts of the high dose region towards the heart leading to worse survival. The most likely cause of shorter survival is a corresponding increase in dose to the heart base. This analysis provides direct evidence of the importance of accurate patient positioning and highlights the significance of the heart base as a dose sensitive organ in thoracic radiotherapy patients with early effects on survival.
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Defining the Role of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer E. Wakeam, 1 S. Stokes, 2 A. Adibfar, 3 N. Leighl, 4 M. Giuliani, 5 T. Varghese, 2 G. Darling 1 1 Toronto General Hospital, Toronto/CA, 2 University of Utah, Salt Lake City, UT/US, 3 University of Toronto, Toronto/CA, 4 Medical Oncology, Princess Margaret Cancer Centre, Toronto/CA, 5 University of Toronto and Princess Margaret Cancer Center, Toronto, AB/CA Background: Large cell neuroendocrine lung cancer (LC-NEC) is a rare, high-grade neuroendocrine tumor. Patterns of adjuvant treatment after surgical resection have not been well defined. Method: Patients with a pathologic diagnosis of LC-NEC were identified in the National Cancer Database 2004-2014. Patient demographics, tumor and treatment characteristics were examined. Survival differences in patients receiving chemotherapy were evaluated using Kaplan-Meier curves, and multivariate hierarchical Cox models were constructed to evaluate the impact of patient, histologic, tumor, treatment and hospital characteristics on overall survival (OS). A conditional landmark of 90-day postoperative survival was used to address immortal time bias and propensity-matching was used to address imbalance in covariates between groups. Result: 1,793 patients were identified with pathologically stage I LC-NEC, of which 482 (26.9%) received adjuvant chemotherapy. Use of adjuvant chemotherapy remained similar across the study period. Patients receiving adjuvant chemo were younger, less comorbid and more likely to have T2 tumors. Significantly longer survival was observed with the receipt of adjuvant chemotherapy (5year OS 59.2% vs. 45.3%), which persisted after adjustment in multivariable Cox models (HR 0.69, 95%CI0.58 e 0.82, p<0.0001). Adjuvant chemotherapy was associated with longer survival in patients with tumors 2-3cm (60.4% vs. 41.8%; HR 0.64, 95%CI 0.46-0.89, p<0.0001), and T2 tumors (59.8% vs. 42.1%; HR 0.63, 95%CI 0.50-0.81, p<0.0001), but no differences were observed for LC-NEC patients with tumor size <2cm. Adjuvant chest radiotherapy was not associated with improved survival. T-stage specific propensity-matching confirmed these findings, however the association between survival and adjuvant chemotherapy for patients with tumors 2-3cm was no longer significant. Conclusion: In this national study of LC-NEC, adjuvant chemotherapy was associated with significantly longer survival in Stage I tumors greater than 2cm. Adjuvant radiation was not associated with survival. A randomized trial of stage T2-4N0 LCNEC is needed to clarify the role of adjuvant chemotherapy in this population. Background: Minimally invasive approaches are increasingly being used for the conduct of complex surgical procedures. Whether the benefits of minimally invasive approaches compared to thoracotomy for sublobar and lobar lung resection for nonsmall cell lung carcinoma are realized for patients undergoing pneumonectomy is not clear. Method: The National Cancer Database was queried for patients who underwent pneumonectomy for NSCLC from 2010-2014. Those who underwent resection by a minimally invasive approach (MIS) were compared with those who were done by thoracotomy (Open) in an intent-to-treat analysis. Associations between potential covariates and treatment were analyzed using the Pearson Chi-square test for categorical variables and Wilcoxon Rank Sum test for continuous variables. Univariable and multivariable logistic models and proportional hazards model were used to assess the effect of surgical approach on 30 day and 90 day mortality and overall survival. Relative prognosis was summarized using odds ratios (OR) and hazards ratios (HR) estimates and 95% confidence limits. Result: A total of 4,938 patients underwent pneumonectomy during the study period, of which 755 (15.3%) were completed by minimally invasive approaches (MIS). No difference was noted in 30 and 90-day mortality rates for MIS compared to Open approaches (6.8% and 12.3% vs 6.7% and 11.9% respectively, p ¼ 0.9 and 0.86). Tumor histology and stage characteristics were similar between the two groups. Mean lymph nodes examined was higher in the MIS group compared to Open (17.1± 0.4 vs 16.1 ± 0.2, p¼0.034). Surgical approach was not associated with any difference in perioperative mortality with univariable or multivariable analysis. MIS was associated with improved overall survival on univariable analysis, but this was not evident with multivariable analysis. Conclusion: Pneumonectomy performed by minimally invasive approaches does not compromise perioperative mortality or long term outcomes. Further investigation into the impact of minimally invasive approaches on perioperative outcomes for whole lung resection is warranted. The standard procedure at our institution for intraoperative localization of non-palpable small lung nodules is computed tomography (CT)-guided microcoil placement prior to video-assisted thoracic surgery (VATS). Typically, microcoil placement is performed in the radiology suite followed by transfer to the operation room (OR). Our institution has built the Guided Therapeutics (GTx) OR, which includes a robotic cone-beam CT (CBCT). The GTx OR allows imaging and therapy to occur in one location. This can improve workflow and reduce patient transportation, which may increase the risk for microcoil dislodgement or the development of pneumothorax/hemothorax. Our objective was to determine the safety and efficacy of CBCT-guided microcoil placement for nodule localization during VATS. Method: This is a single center phase I clinical trial (NCT02496624). Patients with small lung nodules who were candidates for standard CT-guided microcoil localization were enrolled. CBCT was used to generate a 3D reconstruction. The lesion was then segmented using Syngo iGuide software. This reconstruction was next integrated into the digital workspace and automatically registered onto the fluoroscopic images, creating 'augmented fluoroscopy'. The microcoil was placed percutaneously using 'augmented' guidance, proximal to the lesion, using local anesthetic. Patients were subsequently induced into general anesthesia, intubated, and positioned for VATS. Minimally invasive resection of the nodule together with the microcoil was performed under standard fluoroscopic guidance. Result: A total of 11 patients were enrolled (mean age 70 ± 11SD). The average tumor size on CT was 1.3 cm (range 0.9-1.7). The average deepest depth from the pleural surface was 2.3 cm (1.3-3.8). The average CBCT-guided intervention time was 39 minutes (25-54), and VATS procedural time was 54 minutes (14-78). We were able to detect and successfully resect all nodules. Average total radiation dose was in an acceptable low range (8307 mGy*m 2 , range, 2402e18,371). There were no intraoperative complications. Average post-operative length of stay was 1.8 days. A pathological diagnosis was made for all patients: 8 primary lung cancers and 3 lung metastases. All surgical margins were negative on final pathology. Conclusion: CBCT-guided microcoil insertion followed by VATS was safe, with short operative times, short length of stay and 100% diagnostic yield. With the GTx OR's real-time guidance capabilities, surgeons can operate with increased confidence of finding and removing the target lesion. This technique will become increasingly important in the future with growing numbers of small nodules being detected on CT by lung cancer screening programs. Background: Systematic nodal dissection (SND) is an international standard of lymph node dissection for non-small cell lung cancer (NSCLC). Recently, lobe-specific patterns of mediastinal lymph node metastases have been recognized, and lobe-specific nodal dissection (LSD) has been proposed for early-stage NSCLC. The purpose of this study was to assess the surgical outcomes according to the extent of mediastinal lymph node dissection for patients with NSCLC by using a nationwide registry database. Method: From among 11,663 patients in a Japanese lung cancer registry study for 2004, 5392 patients with clinical stage (c-stage) I or II NSCLC that was completely resected by lobectomy and either SND or LSD were enrolled. Patients who received preoperative therapy or had middle lobe tumor were excluded. In the LSD group, inferior mediastinal (subcarinal) nodes were not dissected for upper lobe tumors, and superior mediastinal nodes were not dissected for lower lobe tumors. To reduce the selection bias, an inverse probability of treatment weighting (IPTW) method using a propensity score was implemented. Result: LSD and SND were performed in 1,268 (23.5%) and 4,124 (76.5%) patients, respectively. LSD group included more c-IA and upper lobe tumors relative to SND group, although there was no significant differences in age and preoperative comorbidity. There was no significant difference in postoperative morbidity and mortality between 2 groups. Extended pathological N2 disease outside LSD area was found in 3.2% of the SND group, but recurrences were not different between 2 groups (all recurrences: 22.0% in LSD, 26.9% in SND; local recurrence: 6.1% in LSD, 7.7% in SND; p¼0.788). The 5-year overall survival (OS) was 81.5% in LSD and SND in 75.9%. An IPTWeadjusted Cox model showed that LSD did not have a negative prognostic impact and instead was associated with favorable survival (hazard ratio: 0.68, 95% confidence interval: 0.60-0.77). Conclusion: This retrospective registry study suggested that LSD is an alternative to SND for selected patients with c-stage I or II NSCLC. Future prospective studies are warranted to determine whether LSD is applicable and provides clinical benefit for the general population of patients with cstage I or II NSCLC. Keywords: Lymph node dissection, non-small cell lung cancer, Surgery
